Connection

MOTHAFFAR RIMAWI to Triple Negative Breast Neoplasms

This is a "connection" page, showing publications MOTHAFFAR RIMAWI has written about Triple Negative Breast Neoplasms.
  1. IRE1a silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer. Cell. 2024 Dec 12; 187(25):7248-7266.e34.
    View in: PubMed
    Score: 0.187
  2. Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Mar 01; 10(3):362-371.
    View in: PubMed
    Score: 0.179
  3. Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030. Ann Oncol. 2023 10; 34(10):899-906.
    View in: PubMed
    Score: 0.172
  4. Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins. Cancer Res Commun. 2023 08; 3(8):1551-1563.
    View in: PubMed
    Score: 0.172
  5. Toward Practical Integration of Omic and Imaging Data in Co-Clinical Trials. Tomography. 2023 04 10; 9(2):810-828.
    View in: PubMed
    Score: 0.168
  6. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nat Cancer. 2023 01; 4(1):128-147.
    View in: PubMed
    Score: 0.165
  7. Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. Cancer Discov. 2022 11 02; 12(11):2586-2605.
    View in: PubMed
    Score: 0.163
  8. Immunogenomic?profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. Breast Cancer Res Treat. 2021 Aug; 189(1):187-202.
    View in: PubMed
    Score: 0.149
  9. TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. Ann Oncol. 2020 11; 31(11):1518-1525.
    View in: PubMed
    Score: 0.140
  10. Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nat Med. 2018 05; 24(4):505-511.
    View in: PubMed
    Score: 0.119
  11. Circulating tumor cell analysis in metastatic triple-negative breast cancers. Clin Cancer Res. 2015 Mar 01; 21(5):1098-105.
    View in: PubMed
    Score: 0.095
  12. Lumpectomy followed by radiation improves survival in HER2 positive and triple-negative breast cancer with high tumor-infiltrating lymphocytes compared to mastectomy alone. Cancer Med. 2021 07; 10(14):4790-4795.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.